SCHEMBL23934209

SCHEMBL23934209

Nc1cc(N)cc(C(=O)Nc2cc(N)c3c(c2)C(=O)NC3=O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 4/20 0.47
KMT2A Q03164 11/20 0.46
MEN1 O00255 7/20 0.46
CASP3 P42574 3/20 0.45
CTDSP1 Q9GZU7 2/20 0.44
PKM P14618 2/20 0.41
BRAF P15056 1/20 0.41
POLB P06746 1/20 0.41
CASP2 P42575 1/20 0.40
CASP7 P55210 1/20 0.40
CASP6 P55212 1/20 0.40
CASP8 Q14790 1/20 0.40
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 1/20 0.38
KLK7 P49862 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934210 0.88 KMT2A (0.51) RXFP1KMT2AMEN1CASP3CTDSP1
SCHEMBL23923273 0.87 RXFP1 (0.55) RXFP1KMT2AMEN1CASP3CTDSP1
SCHEMBL23934221 0.85 CASP3 (0.60) RXFP1KMT2AMEN1CASP3CTDSP1
SCHEMBL23934277 0.83 KMT2A (0.49) RXFP1KMT2AMEN1CASP3CTDSP1
SCHEMBL23934294 0.82 CASP3 (0.53) KMT2AMEN1CASP3CASP2CASP7
SCHEMBL6262680 0.81 KMT2A (0.68) RXFP1KMT2AMEN1CASP3CTDSP1
SCHEMBL23934211 0.80 BRAF (0.54) RXFP1KMT2AMEN1CASP3CTDSP1
SCHEMBL23934274 0.80 KMT2A (0.46) RXFP1KMT2AMEN1CASP3CTDSP1
SCHEMBL27099941 0.80 ALDH1A1 (0.41) RXFP1KMT2AMEN1CTDSP1POLB
SCHEMBL23934276 0.79 CASP3 (0.65) KMT2AMEN1CASP3CTDSP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 RXFP1 2817/4885KMT2A 2003/4885MEN1 2490/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 RXFP1 2817/4885KMT2A 2003/4885MEN1 2490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.